Xiaoran Yang

Xiaoran Yang

Auto-generated profile, based on publicly available information

Xiaoran Yang

Avanc Pharmaceutical Co., Ltd, Jinzhou, Liaoning, PR China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2024 in British Journal of Anaesthesia
Verified
Journal Article
Open access
QYQinqin Yin
Qinqin Yin
YYYang Yang
Yang Yang
JLJin Liu
Jin Liu
LLLize Li
Lize Li
XYXiaoran Yang
Xiaoran Yang
XDXiaoqian Deng
Xiaoqian Deng
Methoxyethyl etomidate hydrochloride (ET-26) is a novel etomidate analogue. This is the first-in-human study of a bolus i.v. formulation of ET-26 to assess its safety, tolerability, hypnotic effects, and pharmacokinetics. We enrolled 58 subjects in a dose-escalating study (stage 1a, 10 cohorts, ET-26 0.05-2.8 mg kg-1) and 40 subjects in a head-to-head study (stage 1b, four cohorts). Safety estimates included vital signs, adverse events, physical examination, and laboratory tests. Hypnotic effects were evaluated using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale, bispectral index, loss of eyelash reflex, and response to pain. Adrenocortical function was assessed using plasma total cortisol (PTC), and area above the PTC baseline (AUCPTC) after adrenocorticotropic hormone stimulation. Pharmacokinetics of plasma ET-26 concentrations were investigated. No severe adverse events occurred; the most common adverse events were myoclonus (53.8%) and injection pain (47.4%), which were transient and resolved spontaneously. Vital signs remained stable. ET-26 produced rapid-onset, short-duration unconsciousness. At the 95% effective dose (ED95, 0.8 mg kg-1), ET-26 produced unconsciousness with a similar onset time (1.9 [0.6] min vs 2.1 [1.3] min) and slightly shorter duration (2.9 [0.9] vs 4.8 [1.8]) compared with etomidate 0.3 mg kg-1, and resulted in higher AUCPTC (614 [454] vs -932 [555] nmol h-1). ET-26 showed linear pharmacokinetics, and a two-compartment model best described the pharmacokinetics. ET-26 was tolerated in healthy volunteers up to 2.8 mg kg-1. It produced rapid-onset, short-acting unconsciousness with stable cardiovascular and respiratory properties. Adrenocortical function was better preserved compared with etomidate 0.3 mg kg-1. ChiCTR2100047525 (https://www.chictr.org.cn/index.aspx, ChiCTR2100047525).